AstraZeneca Urges Increase in FDA Funding

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) urged the Obama Administration to increase funding for the Food and Drug Administration’s fiscal year 2012 budget by 20 percent to help the agency effectively manage a growing list of complex public health responsibilities.

“We remain committed to doing what we can to help the FDA meet its needs,” Rich Fante, President AstraZeneca US, wrote in a letter to Health Human Services Secretary Kathleen Sebelius. “But we believe Congress and the President must support this critical need as well by providing the funding the FDA requires to fulfill its mission.”

In supporting an increase in funding for the agency, AstraZeneca seeks to ensure the agency has the resources it needs to effectively oversee the quality and safety of medical treatments, cosmetics and the food supply, while also taking on such serious threats as bioterrorism, the H1N1 influenza virus and other public health emergencies.

AstraZeneca is a founding member of the Alliance for a Stronger FDA, a coalition of patient groups, consumer advocates, biomedical research advocates, health professionals and industry dedicated to increasing FDA’s appropriations.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: or call 1-800-AZandMe (292-6363).


Media Inquiries:
Tony Jewell, 302-885-4594

KEYWORDS:   United States  North America  Delaware

INDUSTRY KEYWORDS:   Health  Biotechnology  Public Policy/Government  Congressional News/Views  Pharmaceutical  FDA



Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.